Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

February 28, 2022

Study Completion Date

April 30, 2031

Conditions
Breast Cancer
Interventions
DRUG

Letrozole

DRUG

Tamoxifen

DRUG

Palbociclib

DRUG

Endocrine Therapy

Trial Locations (11)

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University Medical Center, Nashville

77030

MD Anderson Cancer Center, Houston

06904

Stamford Hospital, Stamford

04412

Eastern Maine Medical Center, Brewer

02135

Dana-Farber at St. Elizabeth's Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01757

DF/BWCC at Milford Regional Medical Center, Milford

02190

DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth

02903

Lifespan, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER